Guided Therapeutics, Inc. (OTCMKTS:GTHP – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 12,300 shares, a drop of 6.1% from the September 30th total of 13,100 shares. Based on an average daily volume of 2,600 shares, the short-interest ratio is currently 4.7 days.
Guided Therapeutics Stock Down 20.0 %
Shares of Guided Therapeutics stock opened at $0.16 on Friday. The company’s fifty day simple moving average is $0.16 and its two-hundred day simple moving average is $0.13. Guided Therapeutics has a 12-month low of $0.06 and a 12-month high of $0.25. The firm has a market cap of $9.76 million, a PE ratio of -5.33 and a beta of 0.52.
Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc, a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light.
Featured Articles
- Five stocks we like better than Guided Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- How to Use the MarketBeat Dividend Calculator
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What Are Growth Stocks and Investing in Them
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.